Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly.
Clin Endocrinol (Oxf)
; 64(2): 209-14, 2006 Feb.
Article
em En
| MEDLINE
| ID: mdl-16430722
ABSTRACT
OBJECTIVE:
During short-term treatment, monthly subcutaneous injections of lanreotide Autogel are effective in controlling GH/IGF-1 hypersecretion and are well tolerated in patients with acromegaly. This study reports the effectiveness and the tolerability of lanreotide Autogel for at least 3 years in acromegalic patients. PATIENTS Fourteen patients (nine females, five males) were treated with titrated doses of lanreotide Autogel.DESIGN:
This clinical study was an extension of a previous trial. After three fixed-dose lanreotide Autogel injections, treatment was adjusted according to mean GH and IGF-I levels. After 3 years of treatment, patients were receiving 120 (n=7), 90 (n=2) and 60 mg (n=4) monthly injections of lanreotide Autogel. MEASUREMENTS Acromegalic symptoms, GH and IGF-1 concentrations were analysed at the end of lanreotide microparticle treatment, and after 4, 8, 12, 24, 30 and 36 months of lanreotide Autogel therapy. Tolerance and side-effects were monitored throughout the 3-year study. RESULTS Hormonal control (GHCONCLUSION:
This 3-year study shows that lanreotide Autogel is effective in controlling GH/IGF-1 hypersecretion and is well tolerated during long-term treatment of patients with acromegaly.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Peptídeos Cíclicos
/
Acromegalia
/
Somatostatina
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2006
Tipo de documento:
Article